Late outcome of a controlled trial of @entity4688 treatment in progressive @entity177 . Hard end-points and influence of XXXX .

@entity1 @entity644 @entity4688 @entity1289 @entity177 @entity454
An earlier controlled trial showed that over an average of 26 months, @entity4688 slowed the progression of @entity177 . Following completion of the trial, the @entity1 continued to receive antihypertensive treatment according to ordinary clinical criteria. All but four @entity1 in the @entity4688 group remained on that drug, and two @entity1 in the control group were switched to an @entity1289 ( @entity1289 ) inhibitor. In the present study the fate of the 70 @entity1 44 months after termination of the trial was investigated, with a total follow-up of around 7 years. In the original @entity4688 group, 12 of the 35 @entity1 (34%) were alive without renal replacement therapy versus five of the 35 @entity1 (14%) in the control group. This difference of 20% in favour of having been in the @entity4688 group in the original trial was significant (P = 0.05; 95% confidence limits 0.5-39.5%). The influence of baseline @entity644 on clinical outcome was analysed. In the original control group, baseline renal clearances of albumin (Calb) and immunoglobulin G (CIgG) were significantly lower in @entity1 surviving without renal replacement therapy at follow-up than in @entity1 who ultimately developed @entity454 ( @entity454 ) (P < 0.05). In the original @entity4688 group, these baseline clearances were equal in the two renal outcome groups. In all @entity1 , baseline Calb and CIgG were negatively correlated with the rate of change in GFR during the controlled trial (r = -0.37, P < 0.01 and r = -0.28, P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
